Objective:Multivariate logistic regression analysis was performed to analyze the risk factors for intensive care unit-acquired weakness (ICU-AW) in critically ill patients.Methods:A total of 220 critically ill patients who were admitted to Intensive Care Unit, The First Hospital of Jiaxing from January 2020 to January 2022 were included in this study. The incidence of ICU-AW was recorded. Univariate analysis was conducted to investigate the factors related to ICU-AW, while multiple logistic regression analysis was performed to identify independent risk factors for ICU-AW in critically ill patients.Results:Among the 220 critically ill patients, 64 developed ICU-AW, resulting in an incidence of 29.1% (64/220). There were no significant differences in sex, age, history of alcoholism, history of smoking, marital status, hypertension, diabetes, or use of glucocorticoid (methylprednisolone sodium succinate for injection) between the ICU-AW group and the non-ICU-AW group (all P > 0.05). The proportion of patients with sepsis in the ICU-AW group was higher than that in the non-ICU-AW group [46.9% (30/64) vs. 15.4% (24/156)]. The proportion of patients who were immobilized in the ICU-AW group was higher than that in the non-ICU-AW group [89.1% (37/64) vs. 64.1% (100/156)]. The use of nerve blocker (vecuronium bromide for injection) was more prevalent in the ICU-AW group than that in the non-ICU-AW group [57.8% (37/64) vs. 23.1% (36/156)]. The Acute Physiology And Chronic Health Evaluation Ⅱ score in the ICU-AW group was higher than that in the non-ICU-AW group [16 (11, 23) vs. 12 (8, 17)]. The duration of mechanical ventilation in the ICU-AW group was longer than that in the non-ICU-AW group [8 (4, 13) days vs. 4 (3, 6) days]. The length of hospital stay in the ICU-AW group was longer than that in the non-ICU-AW group [10 (7, 17) days vs. 7 (5, 11) days]. The blood lactate level in the ICU-AW group was higher than that in the non-ICU-AW group [2 (1, 2) mmol/L vs. 1 (1, 2) mmol/L]. All differences were statistically significant ( χ2 = 24.30, 13.83, 24.70, Z = 3.83, 4.59, 3.97, 2.70, all P < 0.05). The results of the univariate analysis, when included in the multivariate logistic regression analysis, showed that sepsis, immobilization, duration of mechanical ventilation, blood lactate level, and Acute Physiology And Chronic Health Evaluation Ⅱ score were independent risk factors for ICU-AW (all P < 0.05). Conclusions:The incidence of ICU-AW is high and the risk factors for ICU-AW are complex. Therefore, targeted control of high-risk factors should be actively performed to prevent and treat ICU-AW.

A ketogenic diet(KD)refers to an eating pattern designed to achieve a low-calorie content,minimum carbohydrate intake,high-fat consumption,and standard protein levels.A ketogenic diet is used in clinical practice to treat conditions including heart disease,diabetes,obesity,autism,glioblastoma,and other cancers.Although a ketogenic diet has not been recommended for any neurological disorders except epilepsy,extensive recent research suggests that such a diet may have a neuroprotective effect and may thus represent a new dietary therapy for the treatment of Parkinson's disease(PD).In this review,we discuss in detail the mechanisms responsible for the neuroprotective effects of a ketogenic diet in Parkinson's disease,with the aim of providing references for future clinical and experimental studies.

A ketogenic diet(KD)refers to an eating pattern designed to achieve a low-calorie content,minimum carbohydrate intake,high-fat consumption,and standard protein levels.A ketogenic diet is used in clinical practice to treat conditions including heart disease,diabetes,obesity,autism,glioblastoma,and other cancers.Although a ketogenic diet has not been recommended for any neurological disorders except epilepsy,extensive recent research suggests that such a diet may have a neuroprotective effect and may thus represent a new dietary therapy for the treatment of Parkinson's disease(PD).In this review,we discuss in detail the mechanisms responsible for the neuroprotective effects of a ketogenic diet in Parkinson's disease,with the aim of providing references for future clinical and experimental studies.

Objective:Multivariate logistic regression analysis was performed to analyze the risk factors for intensive care unit-acquired weakness (ICU-AW) in critically ill patients.Methods:A total of 220 critically ill patients who were admitted to Intensive Care Unit, The First Hospital of Jiaxing from January 2020 to January 2022 were included in this study. The incidence of ICU-AW was recorded. Univariate analysis was conducted to investigate the factors related to ICU-AW, while multiple logistic regression analysis was performed to identify independent risk factors for ICU-AW in critically ill patients.Results:Among the 220 critically ill patients, 64 developed ICU-AW, resulting in an incidence of 29.1% (64/220). There were no significant differences in sex, age, history of alcoholism, history of smoking, marital status, hypertension, diabetes, or use of glucocorticoid (methylprednisolone sodium succinate for injection) between the ICU-AW group and the non-ICU-AW group (all P > 0.05). The proportion of patients with sepsis in the ICU-AW group was higher than that in the non-ICU-AW group [46.9% (30/64) vs. 15.4% (24/156)]. The proportion of patients who were immobilized in the ICU-AW group was higher than that in the non-ICU-AW group [89.1% (37/64) vs. 64.1% (100/156)]. The use of nerve blocker (vecuronium bromide for injection) was more prevalent in the ICU-AW group than that in the non-ICU-AW group [57.8% (37/64) vs. 23.1% (36/156)]. The Acute Physiology And Chronic Health Evaluation Ⅱ score in the ICU-AW group was higher than that in the non-ICU-AW group [16 (11, 23) vs. 12 (8, 17)]. The duration of mechanical ventilation in the ICU-AW group was longer than that in the non-ICU-AW group [8 (4, 13) days vs. 4 (3, 6) days]. The length of hospital stay in the ICU-AW group was longer than that in the non-ICU-AW group [10 (7, 17) days vs. 7 (5, 11) days]. The blood lactate level in the ICU-AW group was higher than that in the non-ICU-AW group [2 (1, 2) mmol/L vs. 1 (1, 2) mmol/L]. All differences were statistically significant ( χ2 = 24.30, 13.83, 24.70, Z = 3.83, 4.59, 3.97, 2.70, all P < 0.05). The results of the univariate analysis, when included in the multivariate logistic regression analysis, showed that sepsis, immobilization, duration of mechanical ventilation, blood lactate level, and Acute Physiology And Chronic Health Evaluation Ⅱ score were independent risk factors for ICU-AW (all P < 0.05). Conclusions:The incidence of ICU-AW is high and the risk factors for ICU-AW are complex. Therefore, targeted control of high-risk factors should be actively performed to prevent and treat ICU-AW.

Parkinson's disease is a neurodegenerative disease associated with abnormal copper metabolism in the brain,which leads to misfolding and aggregation of α-synuclein-copper complexes,which is an important pathological sign of Parkinson's disease.Copper metabolism,i.e.,cellular metabolic processes involving copper ions,is closely related to the pathogenesis of α-synuclein aggregation,dopamine metabolism,mitochondrial dysfunction,oxidative stress,and ferroptosis in Parkinson's disease.In this review,we summarize the molecular metabolic mechanism of copper toxicity by studying the pathological role of copper metabolism in Parkinson's disease,to support our further understanding of the mechanism of action and drug development.

OBJECTIVE To observe the clinical efficacy of Erdong Xiaoke Formula in the treatment of type 2 diabetes dry eyes with yin deficiency and heat excess syndrome and its effect on serum interleukin 17(IL-17)and interleukin 1β(IL-1β),and to ex-plore the therapeutic mechanism of Erdong Xiaoke Formula.METHODS 110 cases of type 2 diabetes patients with dry eyes of yin deficiency and heat excess syndrome from Jiangsu Province Hospital of Chinese Medicine were enrolled and randomly divided into a treatment group and a control group,55 cases each.5 cases dropped out of the treatment group and 4 cases dropped out of the control group.The control group was given a basic hypoglycemic regimen combined with topical sodium hyaluronate eye drops.The treatment group was given Erdong Xiaoke Formula in addition to the treatment in the control group.The treatment course for both groups was 4 weeks.Changes in TCM syndrome scores of the two groups of patients were observed before and after treatment,and the clinical effica-cy of TCM was evaluated.Blood glucose and pancreatic islet function-related indicators[fasting blood glucose(FBG),fasting insulin(FINS),fasting C-peptide(FCP),postprandial 2 h blood glucose(PBG),insulin secretion function index(HOMA-β),insulin re-sistance index(HOMA)-IR)],ocular surface indicators[tear break up time(BUT),corneal sodium fluorescein staining(FL),Schirmer Ⅰ test(SⅠT)],and inflammation-related indicators(IL-17,IL-1β)were detected.The occurrence of adverse reactions in the two groups of patients was observed during the treatment period.RESULTS After treatment,the total scores of TCM syn-dromes in both groups were significantly reduced(P＜0.01),the treatment group was better than the control group(P＜0.01),and the total effective rate of TCM syndromes in the treatment group was higher than that of the control group(P＜0.01);SⅠT and BUT of pa-tients in both groups increased significantly(P＜0.01),and the treatment group was better than the control group(P＜0.05,P＜0.01);the FL of patients in both groups significantly reduced(P＜0.01),and there was no significant difference between the groups;the ser-um IL-17 and IL-1β of the patients in the treatment group decreased significantly(P＜0.01),which was significantly better than that of the control group(P＜0.05).There were no significant changes in blood glucose and pancreatic islet function-related indicators in the two groups before and after treatment(P＞0.05).During the treatment,no obvious adverse reactions were observed in the two groups.CONCLUSION Erdong Xiaoke Formula can improve SⅠT,BUT,FL and eye symptoms in patients with diabetic dry eye,effectively treat diabetic dry eye,and reduce ocular surface inflammation.Its mechanism may be related to reducing serum inflammato-ry factors IL-17 and IL-1β.

H 1-antihistamines are widely used in the treatment of various allergic diseases, but there are still many challenges in the safe and rational use of H 1-antihistamines in pediatrics, and there is a lack of guidance on the prescription review of H 1-antihistamines for children.In this paper, suggestions are put forward from the indications, dosage, route of administration, pathophysiological characteristics of children with individual difference and drug interactions, so as to provide reference for clinicians and pharmacists.

Objective: To understand the public health emergency response capacity in primary and secondary schools, and to explore the problems and challenges in the prevention and control of public health emergency in primary and secondary schools for specific strategies. Methods: By using the stratified group sampling method, a questionnaire survey on general situation, knowledge, attitude and training, as well as public health emergencies response capacity among 2 988 teachers or leaders responsible for school emergency response in primary and secondary schools from Beijing, Chongqing and Yunnan. Results: Participants varied on their positions, titles, educational background and knowledge accuracy. Higher knowledge accuracy was associated with higher educational background ( χ 2=50.73-203.36, P < 0.05 ). The implementation of regular public health emergency related programs was poorly conducted in high schools (50.0%). Urban schools (42.0%) had higher proportion of qualified health care professionals than rural schools (18.2%), and private schools (48.5%) was higher than public schools (24.7%). The primary challenges included the shortage of guidance from professionals and the lack of related testing equipment (84.91%, 74.03%). Conclusion Although the ability of emergency handling of public health emergencies in schools in the three regions is advancing with the times, there are still many deficiencies, some omissions in the mastery of knowledge. It is suggested to inerease pre service and special training of school health work CDC should strengthen technical guidance and work supervision of infectious disease management in schools.

Abstract OBJECTIVE To determine the index weight, optimize the extraction process of gastropathy oral thick paste 1. METHODS Taking the amount of water added, extraction time and extraction times as factors, depend on the single factor experiment, L9(34) orthogonal table was selected to design the experiment. The content of chlorogenic acid was determined by HPLC and the content of total flavonoids content was determined by ultraviolet spectrophotometry. With the above two contents plus the yield of dry extractum as the evaluation index, the weights were assigned based on the analytic hierarchy process, entropy weight method and independence weight method, and the extraction process was optimized by orthogonal experimental design. RESULTS Multi-index scoring was more scientific and reasonable, and the final optimal extraction conditions for gastropathy oral thick paste 1 were as follows: add 8 times the amount of water, extract twice and 0.5 h for each time. CONCLUSION The optimized extraction process using analytic hierarchy process, entropy weight method and independence weight method is reasonable, feasible, stable, and reproducible, which is suitable for the preparation of gastropathy oral thick paste 1, providing reference for subsequent research and development.

Objective:To assess the clinical effectiveness and safety of Omalizumab for treating pediatric allergic asthma in real world in China.Methods:The clinical data of children aged 6 to 11 years with allergic asthma who received Omalizumab treatment in 17 hospitals in China between July 6, 2018 and September 30, 2020 were retrospectively analyzed.Such information as the demographic characteristics, allergic history, family history, total immunoglobulin E (IgE) levels, specific IgE levels, skin prick test, exhaled nitric oxide (FeNO) levels, eosinophil (EOS) counts, and comorbidities at baseline were collected.Descriptive analysis of the Omalizumab treatment mode was made, and the difference in the first dose, injection frequency and course of treatment between the Omalizumab treatment mode and the mode recommended in the instruction was investigated.Global Evaluation of Treatment Effectiveness (GETE) analysis was made after Omalizumab treatment.The moderate-to-severe asthma exacerbation rate, inhaled corticosteroid (ICS) dose, lung functions were compared before and after Omalizumab treatment.Changes in the Childhood Asthma Control Test (C-ACT) and Pediatric Asthma Quality of Life Questionnaire (PAQLQ) results from baseline to 4, 8, 12, 16, 24, and 52 weeks after Omalizumab treatment were studied.The commodity improvement was assessed.The adverse event (AE) and serious adverse event (SAE) were analyzed for the evaluation of Omalizumab treatment safety.The difference in the annual rate of moderate-to-severe asthma exacerbation and ICS reduction was investigated by using t test.The significance level was set to 0.05.Other parameters were all subject to descriptive analysis.A total of 200 allergic asthma patients were enrolled, including 75.5% ( n=151) males and 24.5% ( n=49) females.The patients aged (8.20±1.81) years. Results:The median total IgE level of the 200 patients was 513.5 (24.4-11 600.0) IU/mL.Their median treatment time with Omalizumab was 112 (1-666) days.Their first dose of Omalizumab was 300 (150-600) mg.Of the 200 cases, 114 cases (57.0%) followed the first Omalizumab dosage recommended in the instruction.After 4-6 months of Omalizumab treatment, 88.5% of the patients enrolled ( n=117) responded to Omalizumab.After 4 weeks of treatment with Omalizumab, asthma was well-controlled, with an increased C-ACT score [from (22.70±3.70) points to (18.90±3.74) points at baseline]. Four-six months after Omalizumab administration, the annual rate of moderate-to-severe asthma exacerbation had a reduction of (2.00±5.68) per patient year( t=4.702 5, P<0.001), the median ICS daily dose was lowered [0 (0-240) μg vs. 160 (50-4 000) μg at baseline] ( P<0.001), the PAQLQ score was improved [(154.90±8.57) points vs. (122.80±27.15) points at baseline], and the forced expiratory volume in one second % predicted (FEV 1%pred) was increased [(92.80±10.50)% vs. (89.70±18.17)% at baseline]. In patients with available evaluations for comorbidities, including allergic rhinitis, atopic dermatitis or eczema, urticaria, allergic conjunctivitis and sinusitis, 92.8%-100.0% showed improved symptoms.A total of 124 AE were reported in 58 (29.0%) of the 200 patients, and the annual incidence was 0(0-15.1) per patient year.In 53 patients who suffered AE, 44 patients (83.0%) and 9 patients (17.0%) reported mild and moderate AE, respectively.No severe AE were observed in patients.The annual incidence of SAE was 0(0-1.9) per patient year.Most common drug-related AE were abdominal pain (2 patients, 1.0%) and fever (2 patients, 1.0%). No patient withdrew Omalizumab due to AE. Conclusions:Omalizumab shows good effectiveness and safety for the treatment of asthma in children.It can reduce the moderate-to-severe asthma exacerbation rate, reduce the ICS dose, improve asthma control levels, and improve lung functions and quality of life of patients.